In the past decade, fragment-based drug discovery (FBDD) has become an established strategy to discover medicinal lead compounds [1][2][3][4][5]. These fragments (sometimes called 'scaffolds' [6]) are small molecules (Figure 1 ), typically with a molecular mass < 300 [7]. There is currently much interest and investment in FBDD in both academia and industry [2,4, 8, 9] , in particular since FBDD offers several potential advantages to develop well-tailored and high-quality lead compounds. Indeed, FBDD has already delivered clinical candidates [10, 11] .
include chemical novelty, binding affinity and ligand efficiency (LE) [24] , whether the binding mode to the target can be visualized, amenability to synthetic chemistry, and, sometimes, clues of a functional profile (e.g., agonist or antagonist [11] ). The weighting of these criteria is, of course, context dependent.
The selected fragment is intuitively seen as the core of its derived chemical series, therefore, its novelty affects the patentability of derived analogs, especially with target classes for which an intellectual property niche is at a premium. The LE for such a core is another important parameter, since a high initial efficiency indicates that the starting fragment makes very favorable interactions with the target, normalized with respect to its number of nonhydrogen atoms. The LE of the initial fragment influences the LE achieved by derived analogs [25] . A high starting LE is preferred because it signals the opportunity to obtain high-affinity lead compounds without adding undue molecular mass, offering a promising start towards oral bioavailability of the derived lead [26] .
Accelerating H2L with structural information
Since most fragments hits have low binding affinities, a first challenge is to increase their affinity substantially, on a pragmatic timescale. This process is greatly facilitated in view of the fragmentbinding mode to its target, usually ascertained by x-ray crystallography [6, 11, 13, 15, 19, 21, [27] [28] [29] [30] . The structure of the bound fragment accelerates the H2L process since it helps to prioritize among an otherwise very large number of elaboration options, including those with respect to target selectivity [11, 30] . Such structure-guided elaboration assumes that the initial binding mode of the fragment is robust and not prone to changes upon derivatization. This requirement is frequently met, especially when the fragments forms asymmetrical polar interactions with the receptor. Yet, counter examples have been described [19, 28, 31, 32] . One may argue that alteration of a binding mode with different substituents only adds to the range of options for H2L progression. In our experience, binding mode switches do not typically [44] . These small molecules are representative of the small size of fragments. Accordingly, these compounds had weak binding affinities for Hsp90. However, visualization of the fragment-binding modes to the protein, combined with molecular modeling and medicinal chemistry, led to the progress of a fragment hit into a potent lead compound, which is now in phase II clinical trials. Hsp90: Heat shock protein 90.
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The structure-based construction of leads from ideally positioned starting points gives the opportunity to tailor those leads for the target from the outset of H2L. Monitoring changes in LE at each step helps select the most efficient substituents for binding, to increase binding affinity while keeping the compound size under control. Smaller compounds tend to have more favorable absorption and distribution properties [26] . Other relevant physicochemical properties, as well as the selectivity profile, can be monitored and influenced incrementally when building from fragment to lead. Indeed a small (unencumbered) starting point offers, in principle, the opportunity to follow an optimal path from hit to lead. The fragment-binding mode gives early indications regarding which bond vectors will be engaged in optimization of binding affinity, and which vectors are amenable to more diverse variations to tune overall physicochemical properties.
Thus, H2L with FBDD contrasts with situations where one is faced with a relatively large hit with mediocre LE, where much effort may be spent redesigning the starting point before productive optimization can be tackled. With HTS hits, an objective of H2L can be to find the minimum active fragment in a complex molecule [16] . Instead, FBDD starts immediately from a suitable core with a promising binding mode and can concentrate more directly on the path to a lead with well-balanced physicochemical properties for druglikeness [4] .
Explore & design with computational chemistry
Seeing how a fragment binds to its target gives a helpful first impression. However, to be most productive, FBDD can exploit the full range of drug-design tools available from modern computational chemistry. When applicable, one spontaneously overlays and visualizes the bound fragment with other, larger, compounds binding to the same site. Larger compounds will typically extend to regions of the binding site not occupied by the fragment; hence, one naturally tries to transfer elements from the larger compound to substitute the smaller fragment. For this to work, the exchanged covalent bonds need to be well aligned in a precise local overlay, and the associated intramolecular effects must also be compatible. These constraints make merging between compounds more difficult than it appears, but there are examples of hybrid compounds evolved from a fragment [9, 13] . The combinatorial hybridization of overlaid ligands has been implemented in the BREED algorithm [33] . It assumes that the binding mode of several (many) potent compounds is available; computational docking can help obtain this information quickly for elaborated compounds reported in the literature, without always having to synthesize and crystallize them.
Another tactic is to enumerate virtual libraries around the fragment core, according to predefined chosen chemistries and with accessible reagents. Then, the virtual library can be docked to the binding site, while enforcing the experimentally determined binding mode of the fragment core [6, 11] . This explores the conformations of the putative substituents around the fragment core and their molecular recognition interactions with the receptor. Although the scoring of such interactions remains crude [34] , it is particularly helpful in such context to prioritize the chemistry effort on the promising fragment derivatives. The strength of this approach can also be its main limitation, when it is driven primarily by ease of synthetic chemistry and reagent accessibility, without maximizing opportunities to meet the structural constraints imposed by the receptor. Thus, the selected synthetic chemistry must take the targeted site into account even before docking of the resulting library, in particular regarding the linkers imposed by the chemistry.
A more general approach would be to use the principles of de novo design methods [35, 36] to guide elaboration of the fragment hits. This strategy is not restricted to a preselected chemistry or list of reagents, and computationally generates ideas directly selected to maximize their structural match to the receptor. Even under the receptor steric constraints, this approach faces a combinatorial explosion producing a vast number of suggestions. The associated chemical diversity and novelty may help, but the large array of generated ideas must be filtered aggressively on defined criteria. Pruning with calculated physicochemical descriptors relating to ADMET properties is straightforward and routine. However, reconciling the algorithmically generated ideas with tractable synthetic chemistry remains a major bottle neck for the de novo approach. Yet, starting from an experimentally discovered fragment core means that this key first step does not have to be tackled computationally. Thus, the de novo engine can operate directly on a validated fragment, to explore its substituents. So, The benefits of constructing leads from fragments hits | Commentary www.future-science.com there is, in principle, a strong complementarity between FBDD and the de novo design strategy. Importantly, the de novo tools are very powerful idea generators. Even if not literally practical, such ideas can form the basis of fruitful discussions to inspire medicinal chemistry efforts.
Growing versus linking
Regardless of the precise techniques used to generate and prioritize ideas, there are two avenues to elaborate fragment hits into leads: growing and linking [37] . Growing refers to the stepwise addition of substituents to a fragment anchor, to target as efficiently as possible the surrounding binding site. Our experience, and discussions with other practitioners, indicate that growing is the most frequent situation, if only because linking requires that two fragments bind to adjacent sites on the target. This second situation is, however, sometimes made possible by the small size of the fragments, and the nature of the target [4, 28, 37, 38] . Ideally, one should obtain an x-ray structure with both fragments bound simultaneously, instead of the fragments crystallized separately, as the binding of one fragment may influence the other [28] . When presented with two fragments bound in proximal pockets, the linking approach attempts to find tethers between them [39] . Examples of linking between fragments have been reported [4, 28, 37, 38] .
Theoretically, linking has long been recognized as a way to gain binding affinity over that of each individual constituent fragment, by reducing the penalty arising from the loss in rotational and translational entropy upon binding [28, [40] [41] [42] . Linked fragments can indeed result in more potent compounds [28, 37, 38] , even without apparent favorable interactions between the linker and receptor [38] . Of course, the linker still needs to be sterically adequate, and selected such that it does not incur internal strain in its bioactive binding mode [28, 37, 38] . Such intramolecular conformational energies can be calculated rather accurately by modern computational chemistry [43] , but predicting the other contributions to the free energy of binding remains challenging [42] . Yet, free-energy calculations were reported to have contributed to some fragment evolutions [11] . The strong complementarity that exists, in principle, between FBDD and perturbation-based rigorous free-energy calculations may become practical in the future.
Future perspective
Overall, FBDD has established itself as a powerful paradigm for the discovery of medicinal leads with desirable properties. With this strategy, the H2L process is arguably as close as one can currently be to rational drug design. It offers realistic opportunities to obtain leads quickly while controlling their properties. Of course, trial and error is still part of FBDD, but structure-based design tools do guide fragment optimization. There are still ample productivity gains to be realized by developing more reliable computational design protocols, integrated with synthetic chemistry.
Another major benefit of FBDD will be to deepen and sharpen our fundamental understanding of molecular recognition. Indeed, fragment elaboration yields vast amount of systematic experimental data combining x-ray structures of protein-ligand complexes and associated binding affinities and kinetics. The mining of such data to dissect the underlying physical chemistry of protein-ligand recognition has only begun. So, documenting well-characterized case studies of fragment elaboration remains invaluable. One hopes that the lessons learned will go beyond empiricism and will ultimately inform the development of more powerful design tools. 
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